Evidence map›Paper›PMID 40037692›Full record

ReviewClinical and molecular hepatology2025

Liver disease trends in the Asia-Pacific region for the next 50 years.

Shuichiro Shiina, Javkhlan Maikhuu, Qing Deng, Terguunbileg Batsaikhan, Lariza Marie Canseco, Maki Tobari, Hitoshi Maruyama, Hiroaki Nagamatsu, Diana Alcantara-Payawal, Rino Gani and 4 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical and molecular hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. [Burden and epidemiological trends of alcohol use disorder and alcoholic liver disease in the Asia-Pacific region].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Shuichiro ShiinaDepartment of Gastroenterology, Juntendo University, Tokyo, Japan.
Javkhlan MaikhuuDepartment of Gastroenterology, Juntendo University, Tokyo, Japan.
Qing DengDepartment of Gastroenterology, Juntendo University, Tokyo, Japan.
Terguunbileg BatsaikhanDepartment of Gastroenterology, Juntendo University, Tokyo, Japan.
Lariza Marie CansecoDepartment of Gastroenterology, Juntendo University, Tokyo, Japan.
Maki TobariDepartment of Gastroenterology, Juntendo University, Tokyo, Japan.
Hitoshi MaruyamaDepartment of Gastroenterology, Juntendo University, Tokyo, Japan.
Hiroaki NagamatsuDepartment of Gastroenterology, Juntendo University, Tokyo, Japan.
Diana Alcantara-PayawalDepartment of Internal Medicine, Fatima University Medical Center, Valenzuela, Philippines.
Rino GaniHepatobiliary Division, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
Yi-Hsiang HuangDepartment of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan.
Tawesak TanwandeeDivision of Gastroenterology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Giovanni GalatiUnit of Clinical Medicine and Hepatology, University Campus Bio-Medico, Rome, Italy.
Yoon Jun KimDepartment of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver disease has emerged as a critical and escalating public health concern worldwide, with the Asia-Pacific region at the forefront of this challenge due to its vast population and diverse socioeconomic landscape. Over the coming five decades, this region will experience profound changes in liver disease patterns, shaped by rapid urbanization, lifestyle modifications, advancements in medical technologies, and evolving public health strategies. This article offers an in-depth analysis of six transformative areas defining the trajectory of liver disease in the region. First, it highlights the alarming rise of metabolic dysfunction-associated fatty liver disease and metabolic dysfunction-associated steatohepatitis, diseases driven by modern lifestyle factors and inherent metabolic susceptibilities. Concurrently, it celebrates the declining burden of viral hepatitis, underscoring the success of sustained public health interventions. However, new challenges are emerging, such as the growing impact of environmental and occupational exposures on liver health. Breakthroughs in genomic and epigenetic research promise to advance precision medicine, offering targeted therapeutic solutions. Additionally, the integration of artificial intelligence, big data, and telemedicine is poised to revolutionize liver disease management, improving accessibility and personalized care. Finally, the article emphasizes the critical role of robust health policies, preventive strategies, and cross-border collaboration in shaping a healthier future. By synthesizing these insights, the study aims to guide innovative and effective responses to the evolving liver disease landscape in the Asia-Pacific region.

Indexed as

Liver DiseasesAsiaHumansLife StyleAsia Pacific regionEpidemiologyForecastingLiver diseasesPrecision medicine

Identifiers

PMID40037692
PMCPMC12260636

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.